Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APAP-CYS Adducts in Liver Embolization
NCT02911961Phase 4Withdrawn
- Sponsor
- Denver Health
- Start
- Aug 2021
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial (2 arms), sponsored by Denver Health. Primary endpoint: Serum Acetaminophen-Cysteine Adduct Concentrations at 14 days. Planned start Aug 2021; status: withdrawn.
Beyond the preview
Go deeper on NCT02911961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911961.